Phreesia (NYSE:PHR) Posts Better-Than-Expected Sales In Q4 But Stock Drops
Healthcare technology company Phreesia (NYSE:PHR) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 15.4% year on year to $109.7 million. The company expects the full year’s revenue to be around $477 million, close to analysts’ estimates. Its GAAP loss of $0.11 per share was 35% above analysts’ consensus estimates.